DEMO, founded in 1965, is a mainstay of Greek pharma and one of its largest companies, accounting for 25 percent of the total investment across the entire Greek pharmaceutical sector. Throughout its long history DEMO has shifted its focus, moved…
In Greece, both innovators and the generics industry find fault with the country’s rebates and clawbacks system, a hold over cost-containment measure from the country’s period of extreme economic turmoil.…
The European Union’s decision to mitigate the effects of the COVID-19 pandemic by launching its Recovery and Resilience Facility (RRF) and moving away from its past austerity policies is particularly…
Faye Kosmopolou of Greek generic industry association PEF discusses Greece’s potential as a pharma manufacturing hub for Southeast Europe post-COVID, the challenges of overcoming low generic penetration rates in the…
One of Greece’s leading domestic pharmaceutical companies, RAFARM has had a stellar recent history, including a momentous entry into the US market. Now looking to establish itself as one of Europe’s major players in ophthalmics and complex injectables, VP Aris Mitsopoulos outlines his ambitious growth plan for the firm and why Greece stands to become a significant pharma manufacturing hub…
Novo Nordisk veteran and president of Greece’s leading industry organisation, the Hellenic Association of Pharmaceutical Companies (SFEE), Olympios Papadimitriou speaks to PharmaBoardroom about the impact of the country’s economic comeback…
DEMO, founded in 1965, is a mainstay of Greek pharma and one of its largest companies, accounting for 25 percent of the total investment across the entire Greek pharmaceutical sector.…
IFET is a unique institution within Greece that acts as the country’s mechanism for securing access to rare disease therapies not available in the market. The organisation also works to…
See our Cookie Privacy Policy Here